The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer

• Published in: Annals of oncology Vol. 21; no. suppl-7; pp. vii211 - vii217
• Main Author: Bookman, M A
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.10.2010
• Subjects: angiogenesis; Calibration; carboplatin; Carcinoma, Ovarian Epithelial; chemotherapy; chemotherapy resistance; dose-density; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - physiology; Drugs, Investigational - therapeutic use; Female; Humans; Molecular Targeted Therapy - methods; Neoadjuvant Therapy - methods; Neoadjuvant Therapy - standards; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - therapy; Neovascularization, Pathologic - drug therapy; ovarian carcinoma; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - therapy; Standard of Care
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdq368

Advanced-stage epithelial ovarian cancer is generally managed with cytoreductive surgery and chemotherapy consisting of carboplatin and paclitaxel, achieving clinical complete remission in the majority of patients. However, most tumors recur, and are associated with progressive chemotherapy resistance. Techniques to optimize chemotherapy have included intraperitoneal administration and weekly scheduling of paclitaxel. Efforts to improve on the long-term results of primary therapy through addition of a third cytotoxic agent have not been successful, including extended maintenance, as well as strategies to overcome chemotherapy resistance. Limited data emerging from phase III trials using bevacizumab suggest some advantage in progression-free survival, particularly in the maintenance setting, and further data are awaited. At present, primary therapy with carboplatin and paclitaxel remains a well-tolerated standard regimen, including the option of weekly paclitaxel dosing, intraperitoneal delivery and neoadjuvant therapy in selected patients. Emerging biological paradigms will hopefully contribute to individualized treatment options in the future.